ANALYSIS OF THE STATE OF PLATELET AGGREGATION IN PREGNANT WOMEN WITH THROMBOPHILIA AND BURDENED OBSTETRIC HISTORY

Authors

  • Olha I. Zalyubovska Department of Clinical Laboratory Diagnostics, Kharkiv National Medical University, Kharkiv, Ukraine
  • Valeriya V. Hryshchenko Department of Clinical Laboratory Diagnostics, Kharkiv National Medical University, Kharkiv, Ukraine

DOI:

https://doi.org/10.21272/eumj.2021;9(4):416-422

Keywords:

pregnant women, burdened obstetric history, thrombophilia, platelet aggregation, ADP inducer

Abstract

The analysis of platelet aggregation in pregnant women with thrombophilia and burdened obstetric history was performed. It has been determined that the development of adverse effects of pregnancy is significantly influenced by conditions such as placental abruption, fetal growth retardation, preeclampsia and fetal death, which are provoked by an abnormal vascular network of the placenta and hemostasis disorders caused by various thromboembolic disorders due to thrombophilia. Therefore, in recent years, the problem of thrombophilia has attracted much attention as a risk factor for pregnancy complications caused by various thromboembolic disorders, which are responsible for preeclampsia, fetoplacental insufficiency, fetal growth retardation and fetal loss, and others.

Given the above, the aim of the work was to analyze the state of platelet aggregation of pregnant women with thrombophilia and burdened obstetric history.

To achieve this goal, a study of pregnant women with thrombophilia and burdened obstetric history was conducted: 137 pregnant women, which were divided into two study groups – the main group, which included 101 pregnant women with a burdened obstetric history and thrombophilia, and the control group, which included 36 pregnant women with a burdened obstetric history without thrombophilia.

The analysis of platelet aggregation of pregnant women with thrombophilia and burdened obstetric history was performed. It was found that the degree of platelet aggregation with the addition of an inducer of adenosine diphosphate at a concentration of 0.0625 prevailed in the control group as compared with pregnant women with thrombophilia (26.3 [24.3; 28.4] % and 21,4 [14,6; 31,1] % in contrast to the aggregation time and its speed (which were lower in the controls (58.0 [54.0; 72.0] s and 22.9 [20.4; 24.9] min) as compared with the main group (71.0 [48.0; 530.5] s) (and 26.5 [14.5; 38.3] min)). It was found that at a concentration of adenosine diphosphate of 0.125, all indicators of platelet aggregation prevailed in the main group (degree of aggregation (35.4 [25.6; 52.5] %; U = 1236.0; p = 0.004), its time (115.0 [47.0; 324.0] s; U = 1623.5; p = 0.341) and speed (45.2 [32.1; 57.5] min; U = 968.5; p < 0.001) compared to the controls (30.1 [26.7; 31.2] %, 84,0 [78.0; 103.5] s and 26.4 [30.4; 35.8] min). It was determined that the concentration of adenosine diphosphate of 0.250 caused an increase in the aggregation time in the control group as compared to the main group (225.5 [196.5; 269.3] s and 181.0 [57.0; 347.0] s; U = 1554.5; p = 0,198) in contrast to the degree [43,3 [39,6; 48.8] % and 51.1 [35.4; 63.8] %; U = 1417.0; p = 0.050) and aggregation rates (57.8 [42.8; 67.0] min and 40.1 [34.4; 47.9] min; U = 786.5; p < 0.001). It was also found that the maximum concentration of adenosine diphosphate (0.500) caused a significant (U = 11178.0; p = 0.002) increase in the aggregation time in the controls (329.0 [269.5; 390.0] s) compared to the main group (211.0 [72.5; 381.0] s) in contrast to the degree and rate of aggregation [51.9 [50.1; 54.3] %; U = 1606.5; p = 0.300 and 42.7 (38.8; 49.4] min; U = 923.5; p < 0.001 and 55.1 [38.6; 69.0] % and 63.6 [44.7; 72.6] min).

Downloads

Download data is not yet available.

Author Biographies

Olha I. Zalyubovska, Department of Clinical Laboratory Diagnostics, Kharkiv National Medical University, Kharkiv, Ukraine

завідувач кафедри клінічної лабораторної діагностики, доктор медичних наук, професор, Харківський національний медичний університет, м. Харків, Україна

Valeriya V. Hryshchenko, Department of Clinical Laboratory Diagnostics, Kharkiv National Medical University, Kharkiv, Ukraine

аспірант кафедри клінічної лабораторної діагностики, Харківський національний медичний університет, м. Харків, Україна

Тел. +380955334024

alex_mischenko1976@ukr.net

References

Pabinger I. Thrombophilia and its impact on pregnancy. Thrombosis Research. 2009;123(3):S16–S21. doi: https://doi.org/10.1016/S0049-3848(09)70128-8

Akinshina S, Makatsariya A, Bitsadze V et al. Thromboprophylaxis in pregnant women with thrombophilia and a history of thrombosis. J Perinat Med. 2018;46(8):893–899. doi: 10.1515/jpm-2017-0329

Croles FN, Nasserinejad K, Duvekot JJ et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017;359:j4452. doi: 10.1136/bmj.j4452

Yang W, Sun Q, Zhou Z et al. Comparison of 2 approaches in management of pregnant women with inherited trombophilias: Prospective analytical cohort study. Medicine (Baltimore). 2019;98(34):e16883. doi: 10.1097/MD.0000000000016883

Lіnnіkov V, Lіnnіkov S. [Thrombophilia as a key to the pathogenesis of accelerated obstetrics and gynecology]. Science and education. 2019;3:31–36. doi: 10.24195/2414-4665-2019-3-5 (In Ukrainian).

Trasca LF, Patrascu N, Bruja R et al. Therapeutic Implications of Inherited Thrombophilia in Pregnancy. Am. J. Ther. 2019;26(3):e364–e374. doi: 10.1097/MJT.0000000000000985

Dłuski D, Mierzyński R, Poniedziałek-Czajkowska E, Leszczyńska-Gorzelak B. Adverse pregnancy outcomes and inherited thrombophilia. J. Perinat. Med. 2018;46(4):411-417. doi: 10.1515/jpm-2017-0059

Baptista FS, de Figueiredo Lemos Bortolotto MR, Marim Bianchini FR et al. Can thrombophilia worsen maternal and perinatal outcomes in cases of severe preeclampsia? Pregnancy Hypertens. 2018;11:81–86. doi: 10.1016/j.preghy.2017.12.012

Bao SH, Chigirin N, Hoch V et al. Uterine Radial Artery Resistance Index Predicts Reproductive Outcome in Women with Recurrent Pregnancy Losses and Thrombophilia. Biomed. Res. Int. 2019;2019:8787010. doi: 10.1155/2019/8787010

Dugalić S, Petronijevic M, Stefanovic A et al. The association between IUGR and maternal inherited thrombophilias: A case-control study. Medicine (Baltimore). 2018;97(41):e12799. doi: 10.1097/MD.0000000000012799

Dargaud Y, Rugeri L, Fleury C et al. Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study. J. Thromb. Haemost. 2017;15(5):897–906. doi: 10.1111/jth.13660

Nahas R, Saliba W, Elias A, Elias M. The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages. Clin. Appl. Thromb. Hemost. 2018;24(1):122–128. doi: 10.1177/1076029616675967

Hotoleanu C. Genetic Risk Factors in Venous Thromboembolism. Adv. Exp. Med. Biol. 2017;906:253–272. doi: 10.1007/5584_2016_120

Yu-Min S, Tsai J, Taiwo E et al. Analysis of Thrombophilia Test Ordering Practices at an Academic Center: A Proposal for Appropriate Testing to Reduce Harm and Cost. Plos One. 2016;11(5):e0155326. doi: 10.1371/journal.pone.0155326

Stevens SM, Woller SC, Bauer KA et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. . J. Thromb. Thrombolysis. 2016;41(1):154–164. doi: 10.1007/s11239-015-1316-1

Dautaj A, Krasi G, Bushati V et al. Hereditary thrombophilia. Acta Biomed. 2019;90(10-S):44–46. doi: 10.23750/abm.v90i10-S.8758.

Mel'nik YUM, ZHuk SІ, Atamanchuk ІM. [Endothelial dysfunction as a marker of placental insufficiency]. Woman's health. 2016;9(115):47–51. (In Ukrainian).

How to Cite

Olha I. Zalyubovska, & Valeriya V. Hryshchenko. (2021). ANALYSIS OF THE STATE OF PLATELET AGGREGATION IN PREGNANT WOMEN WITH THROMBOPHILIA AND BURDENED OBSTETRIC HISTORY. Eastern Ukrainian Medical Journal, 9(4), 416–422. https://doi.org/10.21272/eumj.2021;9(4):416-422